Back to search

Article

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancer

2024-08-28

Abstract excerpt

Immune checkpoint inhibitor immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC). Despite the immense success, still a significant proportion of patients do not develop durable responses, allowing disease progression accompanied by high mortality rates. Therefore, there is an imperative need for identification of reliable non-invasive predictive biomarkers to guide therapeutic decis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c971fffe-4a33-54a7-83f2-684e21dd5ae7
DOI
10.1101/2024.08.27.24312529
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerDOI 10.1101/2024.08.27.24312529
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity
Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity
Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Semantic proximity
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patientSemantic proximity
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancerSemantic proximity
CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and <i>TP53</i> mutationsSemantic proximity
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity
Select a neighboring publication to make it the new centre.